The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
Status:
Terminated
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether maximal estrogen suppression achieved via
the combination of an experimental drug, atamestane, plus an FDA-approved drug, toremifene
(Fareston®), is more effective than another approved drug, letrozole (Femara®), in delaying
the growth of breast cancer, and whether the side effects of the combined hormonal therapy
are different from the side effects of letrozole.